Search
Tropicamide
go.drugbank.com/drugs/DB00809ApprovedTropicamide is an alkaloid atropine‐derived anticholinergic drug and a non‐selective antagonist of muscarinic acetylcholine (mACh) receptors. … [L32178] Oral tropicamide has been investigated as a potential drug to relieve sialorrhea in patients with Parkinson's Disease.[A229958]
Mixtures: Mydrane 0,2 mg/ml + 3,1 mg/ml + 10 mg/ml Injektionslösung, MYDRIASERT 0,28 MG/5,4 MG GÖZ INSERTI ,10 INSERTProducts: MİDAX %1 GÖZ DAMLASI, ÇÖZELTİ, 10 ML, Tropicamide 1% - Liq Oph 10mg/mlFenofibric acid
go.drugbank.com/drugs/DB13873ApprovedInvestigational[A32038,L12855] Due to its high hydrophilicity and poor absorption profile,[A32038] prodrug ,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed … Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia.
Mixtures: FENOVAS®10 MG, FENOVAS®10 MGProducts: TRILIPIX 135 MG, ACIDO FENOFIBRICO 135 MGRaloxifene
go.drugbank.com/drugs/DB00481ApprovedInvestigationalDue to the decline in estrogen levels in postmenopausal osteoporosis, hormone replacement therapy (HRT), such as estradiol, has been used to ameliorate the condition. … However, due to the off-target actions by HRT, newer non-hormonal agents such as raloxifene and [tamoxifen] have been developed to reduce adverse events through selective pharmacological actions on tissue-specific
Categories: Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2C8 InhibitorsProducts: EVISTA TABLET 60 mg, Evista Tablet 60 mgAlogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalChemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. … Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4).
Mixtures: OSENI 25 MG/15 MG TABLETS, OSENI 25 MG/15 MG TABLETSCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis. … Ixazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexProducts: NİNLARO 2.3 MG MG KAPSÜL, 3 ADET, NINLARO® 3.0 MGAgalsidase beta
go.drugbank.com/drugs/DB00103ApprovedInvestigationalWhile patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta. … Agalsidase beta is a recombinant human α-galactosidase A similar to [agalsidase alfa].
Products: FABRAZYME35 MG, REPLAGAL 1 MG/ML IV İNFÜZYONLUK KONSANTRE ÇÖZELTİ, 1 ADETPotassium bicarbonate
go.drugbank.com/drugs/DB11098ApprovedInvestigational[L1836] This FDA denomination classifies potassium bicarbonate as a GRAS ingredient.[L1837] … It is used in medicine as an antacid.[T141] It is registered in the FDA under the section of suitable, safe and effective ingredients for OTC antacids.
Mixtures: POT-K 1,56 G EFERVESAN TABLET, 15 ADET, REFCON ADVANCE 100 MG + 20 MG/ML ORAL SÜSPANSIYONProducts: Effer-K 10 mEq Unflavored, Effer-K 10 mEq Cherry VanillaUrea C-14
go.drugbank.com/drugs/DB09513ApprovedInvestigationalUrea 14C is a urea molecule radiolabelled with a radioactive carbon-14. … It is currently used for the Urea Breath Test (UBT) and is available as a rapid diagnostic test (marketed as PyTest) for the detection of Helicobacter pylori infections.
Products: PYtest ®(Carbon-14-Urea 1.0 microCurie Breath Test)Moroctocog alfa
go.drugbank.com/drugs/DB13999ApprovedMoroctocog alfa is produced through recombinant DNA technology and purification, resulting in a 1438 amino acid, 170 kDa protein [L41170]. … is a fully recombinant factor VIII-Fc fusion protein which has an extended half-life compared with conventional factor VIII due to conjugation to the dimeric Fc domain of human immunoglobulin G1, a long-lived
Products: Xyntha 250 IU Powder and Solvent for Solution for Injection, REFACTO AF 250 IU IV ENJEKSIYONLUK COZELTI ICIN TOZ VE COZUCU FLAKON, 1 ADETOsimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalApproximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. … testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: TAGRISSO® 40 MG, TAGRISSO® 80 MG.